| Dear Fellow Investor, Studies find that multiple purchases by C-level executives signal strong annualized returns.
Spok Holdings, Inc. – SYM: SPOK
Recent Price: $7.20
Insider Action: 6 insiders buy $3.9 mil in shares
Description: Spok Holdings, Inc., through its subsidiary, Spok, Inc., provides healthcare communication solutions in the United States, Europe, Canada, Australia, Asia, and the Middle East. === FDA APPROVAL COULD SEND THIS STOCK SOARING Whenever the FDA approves a new drug... timely investors could see 300-400% returns overnight. Here's the next stock we think wins approval >>> ===
Comstock Resources, Inc. – SYM: CRK
Recent Price: $18.00
Insider Action: 4 insiders buy $2.8 mil in shares
Description: Comstock Resources, Inc., an independent energy company, engages in the acquisition, exploration, development, and production of oil and natural gas primarily in North Louisiana and East Texas, the United States. As of December 31, 2021, the company had 6.1 trillion cubic feet of the natural gas equivalent of proved reserves. It also owns interests in 2,557 producing oil and natural gas wells. The company was incorporated in 1919 and is headquartered in Frisco, Texas.
===
113,548% returns on tiny biotech? (proof below) We are on the cusp of a medical breakthrough. One that will completely change the way we live our lives. There's a drug that Jim Cramer said, “would be the biggest drug ever.” And this tiny Micro-Cap holds the key to this drug that could bring investors as much as 113,548% returns. Sounds crazy? See the proof here>>>
===
Douglas Emmett, Inc. – SYM: DEI
Recent Price: $19.65
Insider Action: 5 insiders buy $8 mil in shares
Description: Douglas Emmett, Inc. (DEI) is a fully integrated, self-administered and self-managed real estate investment trust (REIT), and one of the largest owners and operators of high-quality office and multifamily properties located in the premier coastal submarkets of Los Angeles and Honolulu. Douglas Emmett focuses on owning and acquiring a substantial share of top-tier office properties and premier multifamily communities in neighborhoods that possess significant supply constraints, high-end executive housing and key lifestyle amenities.
=== [BUY ALERT] Our #1 Biotech to Own Right Now Billionaire investors Paul Tudor Jones, Ray Dalio, and Jim Simons have started buying shares of an unknown biotech company. That Goldman Sachs, Morgan Stanley, and Evercore ISI have all given a "BUY" rating. Get Our #1 Biotech Here>>>
=== "The Buck Stops Here,"  Behind the Markets is brought to you by Behind the Markets, LLC. If you have any questions, please contact us at support@behindthemarkets.com, or call at 800-851-1965. Behind the Markets is a newsletter offered to the public on a subscription basis. While subscribers receive the benefit of Behind the Markets opinions, none of the information contained therein constitutes a recommendation from Behind the Markets that any particular security, portfolio of securities, transaction, or investment strategy is suitable for any specific person. You further understand that we will not advise you personally concerning the nature, potential, value or suitability of any particular security, portfolio of securities, transaction, investment strategy or other matter. To the extent any of the information contained in Behind the Markets may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person. Behind the Markets’ past results are not necessarily indicative of future performance.
Employees of Behind the Markets are subject to certain restrictions in transacting for their own benefit. SPECIFICALLY, EMPLOYEES ARE NOT PERMITTED TO BUY OR SELL ANY SECURITY RECOMMENDED FOR THREE (3) TRADING DAYS FOLLOWING THE ISSUE OF A REPORT OR UPDATE.
Behind the Markets’ Newsletter contains Behind the Markets’ own opinions, and none of the information contained therein constitutes a recommendation by Behind the Markets that any particular security, portfolio of securities, transaction, or investment strategy is suitable for any specific person.
You further understand that Behind the Markets will not advise you personally concerning the nature, potential, value or suitability of any particular security, portfolio of securities, transaction, investment strategy or other matter.
To the extent any of the information contained in Behind the Markets Newsletter may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.
Behind the Markets’ past results are not necessarily indicative of future performance. DO NOT EMAIL Behind the Markets SEEKING PERSONALIZED INVESTMENT ADVICE, WHICH WE CANNOT PROVIDE.
The Editor's personal investing goals and risk tolerance may be substantially different from those discussed in the Newsletter and/or circumstances may have changed by the expiration of the three day restricted period, the investment actions taken by the Editor in the accounts the Editor directly or indirectly owns may vary from (and may even be contrary to) the advice and recommendations in the Newsletter.
Investing involves substantial risk. Neither the Editor, the publisher, nor any of their respective affiliates make any guarantee or other promise as to any results that may be obtained from using the Newsletter. While past performance may be analyzed in the Newsletter, past performance should not be considered indicative of future performance.
No subscriber should make any investment decision without first consulting his or her own personal financial advisor and conducting his or her own research and due diligence, including carefully reviewing the prospectus and other public filings of the issuer.
To the maximum extent permitted by law, the Editor, the publisher and their respective affiliates disclaim any and all liability in the event any information, commentary, analysis, opinions, advice and/or recommendations in the Newsletter prove to be inaccurate, incomplete or unreliable, or result in any investment or other losses.
The Newsletter's commentary, analysis, opinions, advice and recommendations represent the personal and subjective views of the Editor and are subject to change at any time
without notice.
The information provided in the Newsletter is obtained from sources which the Editor believes to be reliable. However, the Editor has not independently verified or otherwise investigated all such information. Neither the Editor, the publisher, nor any of their respective affiliates guarantees the accuracy or completeness of any such information.
The Newsletter is not a solicitation or offer to buy or sell any securities. Further, the Newsletter is in no way intended to be a solicitation for any services offered by Behind the Markets
Neither the Editor, the publisher, nor any of their respective affiliates are responsible for any errors or omissions in the Newsletter. |
No comments:
Post a Comment